Variations in the genes CYP3A4, CYP2C9, ABCB1, and ABCG2 significantly influence the pharmacokinetics of rimegepant, a CGRP receptor antagonist used to treat migraines. Polymorphisms in these genes affect the drug's metabolism, clearance, bioavailability, and distribution, consequently impacting its efficacy and safety.